Thanks, good and Joe, everyone. morning,
XXXX August FDA CMO be of API which Heparin may inspections primary at As complete or that required DefenCath received CorMedix and our primary in during stated in you satisfactory letter know, our of supplier approved. identified the resolution NDA CRL FDA a deficiencies before response
As June we the primary FDA the includes month, our been to and report this effectiveness announced observations earlier actions submitted closeout CorMedix data been CMO XXXX a advised by corrective to inspectional that in demonstrate corrective has has implemented have the for actions. all FDA of that issued of
FDA report. that Subsequent of has receipt to announcement, March our closeout acknowledged the Xnd
they Heparin of their implementation non-heparin supplier XXXX primary our too CorMedix corrective arising warning from completed actions API Additionally, has have for June, a letter that informed API.
made the of Although, any of we DefenCath a with API by formal heparin to letter resolution absence NDA. master manufacturing warning block and not supplier the or deficiencies by continue the drug process Heparin the timing file is unclear, FDA DMF the should of that the heparin updates filed or the believe of resubmission with FDA to
we felt prudent blocking issues these was guidance it these the to resubmission NDA. on FDA's seek prior two DefenCath of Given developments, to critical pathway
NDA of FDA Type A potential we resubmission blocking As issues. these the to timing discuss with and a requested Joe of pathway DefenCath meeting indicated,
is means for that mid-April, of of request the discretionary has a are within is FDA FDA deemed which that XX it date meeting the grateful very meeting, it and and granted meetings scheduled Type been submission know, you request. our in we days which As are pleased A
We two are questions. seeking FDA’s concurrence on
report asks first the submitted the question inspection. this inspectional and of at now primary resubmission deficiencies DefenCath CMO for FDA The addressed for closure the that on the NDA from agreement our pre-approval observations the time, has
heparin resubmit the the without has The deficiencies updated second question of can and the asks resolution cited the DefenCath outstanding heparin. Letter API CorMedix Letter that been no primary Warning were application for heparin of because our quality or utilizing manufacturing FDA for process agreement the the in Warning formal DMF supplier
the the with Heparin the part by with Furthermore, on strict of confirm sodium is conducts which structural testing which process. with contamination the heparin, batch to confirmed sets USP for of impurities, API a standards manufactured XXX% compliance USP CMO as receiving the requirements all monograph manufacturer. to testing parameters, and are comply
raise XX-day only affirmative resubmission Class CorMedix primary on CMO. application our to new resubmit utilizing and An clear manufacturing CorMedix with with information our to intends FDA a If X the requests no on a as both NDA, for generated review. questions, quickly first API question would heparin resubmit data the the DefenCath at primary of answer CMO a to new designation source
classified the submission submission as of would period. would require type X a additional this be to we As it information Class reviewed six-month be expect review to a with manufacturing FDA, by
data end validation new to with manufacturing has of of for expects API completed CorMedix heparin available source and of already have by the submission the April. this
on these pathway intends as CorMedix said, soon possible issues. as following guidance application resubmit As the I FDA’s blocking to two
Matt, a I now over financial update. the would turn provide call to to will Matt? like who
